{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,2]],"date-time":"2026-09-02T05:19:33Z","timestamp":1788326373236,"version":"build-2803163510"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T00:00:00Z","timestamp":1530057600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["P01 CA049639"],"award-info":[{"award-number":["P01 CA049639"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2018,11]]},"DOI":"10.1007\/s00277-018-3402-x","type":"journal-article","created":{"date-parts":[[2018,6,27]],"date-time":"2018-06-27T15:32:44Z","timestamp":1530113564000},"page":"2071-2080","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["The co-occurrence of driver mutations in chronic myeloproliferative neoplasms"],"prefix":"10.1007","volume":"97","author":[{"given":"Prajwal","family":"Boddu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Chihara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Masarova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naveen","family":"Pemmaraju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keyur P.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Srdan","family":"Verstovsek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,6,27]]},"reference":[{"issue":"10","key":"3402_CR1","doi-asserted-by":"publisher","first-page":"3370","DOI":"10.1182\/blood-2005-05-1800","volume":"106","author":"J Jelinek","year":"2005","unstructured":"Jelinek J, Oki Y, Gharibyan V, Bueso-Ramos C, Prchal JT, Verstovsek S, Beran M, Estey E, Kantarjian HM, Issa JP (2005) JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome-negative CML, and megakaryocytic leukemia. Blood 106(10):3370\u20133373","journal-title":"Blood"},{"issue":"5","key":"3402_CR2","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/sj.leu.2404993","volume":"22","author":"K Hussein","year":"2008","unstructured":"Hussein K, Bock O, Theophile K, Seegers A, Arps H, Basten O, Grips KH, Franz-Werner J, B\u00fcsche G, Kreipe H (2008) Chronic myeloproliferative diseases with concurrent BCR-ABL junction and JAK2V617F mutation. Leukemia 22(5):1059\u20131062","journal-title":"Leukemia"},{"issue":"5","key":"3402_CR3","doi-asserted-by":"publisher","first-page":"E25","DOI":"10.3816\/CLM.2009.n.080","volume":"9","author":"SR Pingali","year":"2009","unstructured":"Pingali SR et al (2009) Emergence of chronic myelogenous leukemia from a background of myeloproliferative disorder: JAK2V617F as a potential risk factor for BCR-ABL translocation. Clin Lymphoma Myeloma 9(5):E25\u2013E29","journal-title":"Clin Lymphoma Myeloma"},{"issue":"7","key":"3402_CR4","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1182\/blood-2012-11-467787","volume":"121","author":"X Wang","year":"2013","unstructured":"Wang X, Tripodi J, Kremyanskaya M, Blouin A, Roda P, Hoffman R, Najfeld V (2013) BCR-ABL1 is a secondary event after JAK2V617F in patients with polycythemia vera who develop chronic myeloid leukemia. Blood 121(7):1238\u20131239","journal-title":"Blood"},{"key":"3402_CR5","doi-asserted-by":"publisher","DOI":"10.1038\/bcj.2015.77","volume":"5","author":"A Zhou","year":"2015","unstructured":"Zhou A, Knoche EM, Engle EK, Fisher DAC, Oh ST (2015) Concomitant JAK2 V617F-positive polycythemia vera and BCR-ABL-positive chronic myelogenous leukemia treated with ruxolitinib and dasatinib. Blood Cancer J 5:e351","journal-title":"Blood Cancer J"},{"issue":"7","key":"3402_CR6","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1038\/sj.leu.2405088","volume":"22","author":"N Cambier","year":"2008","unstructured":"Cambier N, Renneville A, Cazaentre T, Soenen V, Cossement C, Giraudier S, Grardel N, La\u00ef JL, Rose C, Preudhomme C (2008) JAK2V617F-positive polycythemia vera and Philadelphia chromosome-positive chronic myeloid leukemia: one patient with two distinct myeloproliferative disorders. Leukemia 22(7):1454\u20131455","journal-title":"Leukemia"},{"issue":"6","key":"3402_CR7","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.3324\/haematol.2013.102525","volume":"99","author":"A Iurlo","year":"2014","unstructured":"Iurlo A, Gianelli U, Rapezzi D, Cattaneo D, Fermo E, Binda F, Santambrogio E, Bucelli C, Cortelezzi A (2014) Imatinib and ruxolitinib association: first experience in two patients. Haematologica 99(6):e76\u2013e77","journal-title":"Haematologica"},{"issue":"1","key":"3402_CR8","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1007\/s12185-009-0471-6","volume":"91","author":"PC Bee","year":"2010","unstructured":"Bee PC, Gan GG, Nadarajan VS, Latiff NA, Menaka N (2010) A man with concomitant polycythaemia vera and chronic myeloid leukemia: the dynamics of the two disorders. Int J Hematol 91(1):136\u2013139","journal-title":"Int J Hematol"},{"issue":"1","key":"3402_CR9","doi-asserted-by":"publisher","first-page":"74","DOI":"10.4103\/0300-1652.149177","volume":"56","author":"A Hassan","year":"2015","unstructured":"Hassan A, Dogara LG, Babadoko AA, Awwalu S, Mamman AI (2015) Coexistence of JAK2 and BCR-ABL mutation in patient with myeloproliferative neoplasm. Niger Med J 56(1):74\u201376","journal-title":"Niger Med J"},{"issue":"21","key":"3402_CR10","doi-asserted-by":"publisher","first-page":"3360","DOI":"10.1182\/blood-2015-03-632893","volume":"125","author":"S Loghavi","year":"2015","unstructured":"Loghavi S, Pemmaraju N, Kanagal-Shamanna R, Mehrotra M, Medeiros LJ, Luthra R, Lin P, Huh Y, Kantarjian HM, Cortes JE, Verstovsek S, Patel KP (2015) Insights from response to tyrosine kinase inhibitor therapy in a rare myeloproliferative neoplasm with CALR mutation and BCR-ABL1. Blood 125(21):3360\u20133363","journal-title":"Blood"},{"issue":"10","key":"3402_CR11","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1016\/S1470-2045(07)70295-4","volume":"8","author":"Monica Bocchia","year":"2007","unstructured":"Bocchia, M., Vannucchi A.M., Gozzetti A., Guglielmelli P., Poli G., Crupi R., Defina M., Bosi A., Francesco L., Insights into JAK2-V617F mutation in CML. Lancet Oncol, 2007. 8(10): p. 864\u20136, 866","journal-title":"The Lancet Oncology"},{"issue":"11","key":"3402_CR12","doi-asserted-by":"publisher","first-page":"e212","DOI":"10.1016\/j.leukres.2009.06.011","volume":"33","author":"L Campiotti","year":"2009","unstructured":"Campiotti L, Appio L, Solbiati F, Ageno W, Venco A (2009) JAK2-V617F mutation and Philadelphia positive chronic myeloid leukemia. Leuk Res 33(11):e212\u2013e213","journal-title":"Leuk Res"},{"issue":"7","key":"3402_CR13","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1016\/S1470-2045(07)70206-1","volume":"8","author":"A Kramer","year":"2007","unstructured":"Kramer A et al (2007) JAK2-V617F mutation in a patient with Philadelphia-chromosome-positive chronic myeloid leukaemia. Lancet Oncol 8(7):658\u2013660","journal-title":"Lancet Oncol"},{"issue":"1","key":"3402_CR14","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/2162-3619-2-24","volume":"2","author":"F Pastore","year":"2013","unstructured":"Pastore F, Schneider S, Christ O, Hiddemann W, Spiekermann K (2013) Impressive thrombocytosis evolving in a patient with a BCR-ABL positive CML in major molecular response during dasatinib treatment unmasks an additional JAK2V617F. Exp Hematol Oncol 2(1):24","journal-title":"Exp Hematol Oncol"},{"issue":"5","key":"3402_CR15","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1038\/sj.leu.2404591","volume":"21","author":"M Inami","year":"2007","unstructured":"Inami M, Inokuchi K, Okabe M, Kosaka F, Mitamura Y, Yamaguchi H, Dan K (2007) Polycythemia associated with the JAK2V617F mutation emerged during treatment of chronic myelogenous leukemia. Leukemia 21(5):1103\u20131104","journal-title":"Leukemia"},{"issue":"2","key":"3402_CR16","doi-asserted-by":"publisher","first-page":"276","DOI":"10.1111\/bjh.12969","volume":"167","author":"G McGaffin","year":"2014","unstructured":"McGaffin G, Harper K, Stirling D, McLintock L (2014) JAK2 V617F and CALR mutations are not mutually exclusive; findings from retrospective analysis of a small patient cohort. Br J Haematol 167(2):276\u2013278","journal-title":"Br J Haematol"},{"issue":"7","key":"3402_CR17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1038\/leu.2014.3","volume":"28","author":"A Tefferi","year":"2014","unstructured":"Tefferi A, Lasho TL, Finke CM, Knudson RA, Ketterling R, Hanson CH, Maffioli M, Caramazza D, Passamonti F, Pardanani A (2014) CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia 28(7):1472\u20131477","journal-title":"Leukemia"},{"issue":"14","key":"3402_CR18","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1182\/blood-2013-11-537167","volume":"123","author":"P Lundberg","year":"2014","unstructured":"Lundberg P, Karow A, Nienhold R, Looser R, Hao-Shen H, Nissen I, Girsberger S, Lehmann T, Passweg J, Stern M, Beisel C, Kralovics R, Skoda RC (2014) Clonal evolution and clinical correlates of somatic mutations in myeloproliferative neoplasms. Blood 123(14):2220\u20132228","journal-title":"Blood"},{"issue":"1","key":"3402_CR19","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1182\/blood-2008-01-131664","volume":"112","author":"PA Beer","year":"2008","unstructured":"Beer PA, Campbell PJ, Scott LM, Bench AJ, Erber WN, Bareford D, Wilkins BS, Reilly JT, Hasselbalch HC, Bowman R, Wheatley K, Buck G, Harrison CN, Green AR (2008) MPL mutations in myeloproliferative disorders: analysis of the PT-1 cohort. Blood 112(1):141\u2013149","journal-title":"Blood"},{"issue":"3","key":"3402_CR20","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1111\/j.1365-2141.2007.06565.x","volume":"137","author":"P Guglielmelli","year":"2007","unstructured":"Guglielmelli P, Pancrazzi A, Bergamaschi G, Rosti V, Villani L, Antonioli E, Bosi A, Barosi G, Vannucchi AM, GIMEMA--Italian Registry of Myelofibrosis, MPD Research Consortium (2007) Anaemia characterises patients with myelofibrosis harbouring Mpl mutation. Br J Haematol 137(3):244\u2013247","journal-title":"Br J Haematol"},{"issue":"5","key":"3402_CR21","doi-asserted-by":"publisher","first-page":"781","DOI":"10.1093\/annonc\/mdf156","volume":"13","author":"WI Lee","year":"2002","unstructured":"Lee WI, Kantarjian H, Glassman A, Talpaz M, Lee MS (2002) Quantitative measurement of BCR\/abl transcripts using real-time polymerase chain reaction. Ann Oncol 13(5):781\u2013788","journal-title":"Ann Oncol"},{"issue":"1","key":"3402_CR22","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1309\/AJCPD7NR2RMNQDVF","volume":"135","author":"KP Patel","year":"2011","unstructured":"Patel KP, Ravandi F, Ma D, Paladugu A, Barkoh BA, Medeiros LJ, Luthra R (2011) Acute myeloid leukemia with IDH1 or IDH2 mutation: frequency and clinicopathologic features. Am J Clin Pathol 135(1):35\u201345","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"3402_CR23","doi-asserted-by":"publisher","first-page":"732","DOI":"10.1002\/ajh.24072","volume":"90","author":"CD DiNardo","year":"2015","unstructured":"DiNardo CD, Ravandi F, Agresta S, Konopleva M, Takahashi K, Kadia T, Routbort M, Patel KP, Mark Brandt, Pierce S, Garcia-Manero G, Cortes J, Kantarjian H (2015) Characteristics, clinical outcome, and prognostic significance of IDH mutations in AML. Am J Hematol 90(8):732\u2013736","journal-title":"Am J Hematol"},{"key":"3402_CR24","doi-asserted-by":"crossref","unstructured":"McGowan-Jordan A,S.M., Schmid M. An international system for human cytogenetic normenclature (ISCN 2016), recommendations of the international standing committee on human cytogenetic normenclature, Karger, Base, Switzerland (2016 )","DOI":"10.1159\/isbn.978-3-318-05979-3"},{"issue":"Suppl 3","key":"3402_CR25","first-page":"S45","volume":"17","author":"C Biernaux","year":"1996","unstructured":"Biernaux C et al (1996) Very low level of major BCR-ABL expression in blood of some healthy individuals. Bone Marrow Transplant 17(Suppl 3):S45\u2013S47","journal-title":"Bone Marrow Transplant"},{"issue":"9","key":"3402_CR26","doi-asserted-by":"crossref","first-page":"3362","DOI":"10.1182\/blood.V92.9.3362","volume":"92","author":"S Bose","year":"1998","unstructured":"Bose S, Deininger M, Gora-Tybor J, Goldman JM, Melo JV (1998) The presence of typical and atypical BCR-ABL fusion genes in leukocytes of normal individuals: biologic significance and implications for the assessment of minimal residual disease. Blood 92(9):3362\u20133367","journal-title":"Blood"},{"issue":"1\u20132","key":"3402_CR27","doi-asserted-by":"publisher","first-page":"77","DOI":"10.3109\/10428199909093727","volume":"33","author":"A Aviram","year":"1999","unstructured":"Aviram A, Blickstein D, Stark P, Luboshitz J, Bairey O, Prokocimer M, Shaklai M (1999) Significance of BCR-ABL transcripts in bone marrow aspirates of Philadelphia-negative essential thrombocythemia patients. Leuk Lymphoma 33(1\u20132):77\u201382","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3402_CR28","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.lab.2003.10.007","volume":"143","author":"HC Hsu","year":"2004","unstructured":"Hsu HC, Tan LY, Au LC, Lee YM, Lieu CH, Tsai WH, You JY, Liu MD, Ho CK (2004) Detection of bcr-abl gene expression at a low level in blood cells of some patients with essential thrombocythemia. J Lab Clin Med 143(2):125\u2013129","journal-title":"J Lab Clin Med"},{"issue":"7","key":"3402_CR29","doi-asserted-by":"crossref","first-page":"2420","DOI":"10.1182\/blood.V93.7.2420","volume":"93","author":"S Hackwell","year":"1999","unstructured":"Hackwell S, Ross F, Cullis JO (1999) Patients with essential thrombocythemia do not express BCR-ABL transcripts. Blood 93(7):2420\u20132421","journal-title":"Blood"},{"issue":"4","key":"3402_CR30","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1046\/j.0007-1048.2002.03343.x","volume":"116","author":"G Damaj","year":"2002","unstructured":"Damaj G, Delabesse E, le Bihan C, Asnafi V, Rachid M, Lefrere F, Radford-Weiss I, Macintyre E, Hermine O, Varet B (2002) Typical essential thrombocythaemia does not express bcr-abelson fusion transcript. Br J Haematol 116(4):812\u2013816","journal-title":"Br J Haematol"},{"issue":"11","key":"3402_CR31","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1093\/jjco\/hyd122","volume":"30","author":"H Yamada","year":"2000","unstructured":"Yamada H, Murakami T, Kaneda T, Tadachi M, Utsumi M, Minami S, Hamaguchi M, Kasai M, Kodera Y, Ohashi H, Morishita Y, Terasawa T, Yamasaki Y, Kamiya Y, Hattori M, Yamanaka K, Tsushita K, Shimoyama M (2000) Clinical significance of major and minor bcr\/abl chimeric transcripts in essential thrombocythemia. Jpn J Clin Oncol 30(11):472\u2013477","journal-title":"Jpn J Clin Oncol"},{"issue":"1","key":"3402_CR32","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/0165-4608(94)00108-1","volume":"89","author":"YL Kwong","year":"1996","unstructured":"Kwong YL, Chiu EKW, Liang RHS, Chan V, Chan TK (1996) Essential thrombocythemia with BCR\/ABL rearrangement. Cancer Genet Cytogenet 89(1):74\u201376","journal-title":"Cancer Genet Cytogenet"},{"issue":"6","key":"3402_CR33","doi-asserted-by":"publisher","first-page":"1990","DOI":"10.1182\/blood.V98.6.1990","volume":"98","author":"P Heller","year":"2001","unstructured":"Heller P, Kornblihtt LI, Cuello MT, Larripa I, Najfeld V, Molinas FC (2001) BCR-ABL transcripts may be detected in essential thrombocythemia but lack clinical significance. Blood 98(6):1990\u20131991","journal-title":"Blood"},{"issue":"1","key":"3402_CR34","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1046\/j.1365-2559.2003.01516.x","volume":"42","author":"L Pajor","year":"2003","unstructured":"Pajor L, Kereskai L, Zsdral K, Nagy Z, Vass JA, Jakso P, Radvanyi G (2003) Philadelphia chromosome and\/or bcr-abl mRNA-positive primary thrombocytosis: morphometric evidence for the transition from essential thrombocythaemia to chronic myeloid leukaemia type of myeloproliferation. Histopathology 42(1):53\u201360","journal-title":"Histopathology"},{"issue":"1","key":"3402_CR35","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1007\/s002920050073","volume":"16","author":"R Nafe","year":"1995","unstructured":"Nafe R et al (1995) Morphometry of megakaryocytes for supporting the histologic diagnosis of chronic myeloproliferative diseases. Pathologe 16(1):34\u201340","journal-title":"Pathologe"},{"issue":"2","key":"3402_CR36","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1309\/AJCPUN89CXERVOVH","volume":"132","author":"JW Vardiman","year":"2009","unstructured":"Vardiman JW (2009) Chronic myelogenous leukemia, BCR-ABL1+. Am J Clin Pathol 132(2):250\u2013260","journal-title":"Am J Clin Pathol"},{"issue":"8","key":"3402_CR37","doi-asserted-by":"publisher","first-page":"1824","DOI":"10.1038\/sj.leu.2404730","volume":"21","author":"M Bornhauser","year":"2007","unstructured":"Bornhauser M et al (2007) Concurrent JAK2(V617F) mutation and BCR-ABL translocation within committed myeloid progenitors in myelofibrosis. Leukemia 21(8):1824\u20131826","journal-title":"Leukemia"},{"issue":"1","key":"3402_CR38","doi-asserted-by":"publisher","first-page":"3","DOI":"10.20892\/j.issn.2095-3941.2016.0004","volume":"13","author":"SP Strom","year":"2016","unstructured":"Strom SP (2016) Current practices and guidelines for clinical next-generation sequencing oncology testing. Cancer Biol Med 13(1):3\u201311","journal-title":"Cancer Biol Med"},{"issue":"5","key":"3402_CR39","doi-asserted-by":"publisher","first-page":"683","DOI":"10.1111\/j.1365-2141.2006.06348.x","volume":"135","author":"TL Lasho","year":"2006","unstructured":"Lasho TL, Pardanani A, McClure RF, Mesa RA, Levine RL, Gary Gilliland D, Tefferi A (2006) Concurrent MPL515 and JAK2V617F mutations in myelofibrosis: chronology of clonal emergence and changes in mutant allele burden over time. Br J Haematol 135(5):683\u2013687","journal-title":"Br J Haematol"},{"issue":"23","key":"3402_CR40","doi-asserted-by":"crossref","first-page":"5211","DOI":"10.1182\/blood.V126.23.5211.5211","volume":"126","author":"K Gundabolu","year":"2015","unstructured":"Gundabolu K et al (2015) Concurrent somatic mutations in exon 14 of Janus KINASE2 (JAK2) and exon 10 of myeloprolifeative leukemia virus oncogene (MPL) in myeloproliferative neoplasms (MPN) and myelodysplastic syndromes (MDS)\/MPN. Blood 126(23):5211\u20135211","journal-title":"Blood"},{"issue":"4","key":"3402_CR41","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1002\/ajh.21627","volume":"85","author":"C Martinaud","year":"2010","unstructured":"Martinaud C, Brisou P, Mozziconacci MJ (2010) Is the JAK2(V617F) mutation detectable in healthy volunteers? Am J Hematol 85(4):287\u2013288","journal-title":"Am J Hematol"},{"issue":"9","key":"3402_CR42","doi-asserted-by":"publisher","first-page":"1622","DOI":"10.1038\/sj.leu.2404292","volume":"20","author":"P Sidon","year":"2006","unstructured":"Sidon P, el Housni H, Dessars B, Heimann P (2006) The JAK2V617F mutation is detectable at very low level in peripheral blood of healthy donors. Leukemia 20(9):1622","journal-title":"Leukemia"},{"issue":"1","key":"3402_CR43","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1111\/bjh.12099","volume":"160","author":"C Nielsen","year":"2013","unstructured":"Nielsen C, Birgens HS, Nordestgaard BG, Bojesen SE (2013) Diagnostic value of JAK2 V617F somatic mutation for myeloproliferative cancer in 49 488 individuals from the general population. Br J Haematol 160(1):70\u201379","journal-title":"Br J Haematol"},{"issue":"3","key":"3402_CR44","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1182\/blood-2015-07-661835","volume":"127","author":"JD Milosevic Feenstra","year":"2016","unstructured":"Milosevic Feenstra JD, Nivarthi H, Gisslinger H, Leroy E, Rumi E, Chachoua I, Bagienski K, Kubesova B, Pietra D, Gisslinger B, Milanesi C, Jager R, Chen D, Berg T, Schalling M, Schuster M, Bock C, Constantinescu SN, Cazzola M, Kralovics R (2016) Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood 127(3):325\u2013332","journal-title":"Blood"},{"issue":"6","key":"3402_CR45","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.3109\/10428194.2015.1091932","volume":"57","author":"RH Nussenzveig","year":"2016","unstructured":"Nussenzveig RH, Pham HT, Perkins SL, Prchal JT, Agarwal AM, Salama ME (2016) Increased frequency of co-existing JAK2 exon-12 or MPL exon-10 mutations in patients with low JAK2(V617F) allelic burden. Leuk Lymphoma 57(6):1429\u20131435","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"3402_CR46","doi-asserted-by":"publisher","first-page":"1092","DOI":"10.1182\/blood-2007-04-083501","volume":"110","author":"A Tefferi","year":"2007","unstructured":"Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G, Verstovsek S, Birgegard G, Mesa R, Reilly JT, Gisslinger H, Vannucchi AM, Cervantes F, Finazzi G, Hoffman R, Gilliland DG, Bloomfield CD, Vardiman JW (2007) Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 110(4):1092\u20131097","journal-title":"Blood"},{"issue":"6","key":"3402_CR47","doi-asserted-by":"publisher","first-page":"E41","DOI":"10.3816\/CLM.2009.n.102","volume":"9","author":"Carmen Fava","year":"2009","unstructured":"Favaa C, C.G., Ferrero D, Ulisciania S, Serraa A, Coexistence of a JAK2 mutated clone may cause hematologic resistance to tyrosine kinase inhibitors in chronic myeloid leukemia. Clin Lymphoma Myeloma, 2009. 9 (6): p. E41","journal-title":"Clinical Lymphoma and Myeloma"},{"issue":"1","key":"3402_CR48","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00277-017-3165-9","volume":"97","author":"P Boddu","year":"2018","unstructured":"Boddu P, Masarova L, Verstovsek S, Strati P, Kantarjian H, Cortes J, Estrov Z, Pierce S, Pemmaraju N (2018) Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms. Ann Hematol 97(1):109\u2013121","journal-title":"Ann Hematol"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-018-3402-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-018-3402-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,4]],"date-time":"2020-11-04T12:50:36Z","timestamp":1604494236000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-018-3402-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,6,27]]},"references-count":48,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2018,11]]}},"alternative-id":["3402"],"URL":"https:\/\/doi.org\/10.1007\/s00277-018-3402-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,6,27]]},"assertion":[{"value":"12 June 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}